Urology Times | News & Insights for Urologists & Health …
网页By Hannah Clarke. September 16th 2024. Radium223, chemotherapy improves mCRPC quality of life in phase 2 RAPSON. By Kevin Kunzmann. September 16th 2024. SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC. By Kevin Kunzmann. September 16th 2024. NIAGARA: Durvalumab plus chemo improves EFS and OS in …
Urology Times Journal
网页Urology Times® delivers analysis, perspectives, and practical advice about current health policy issues, clinical advances, and business challenges to urologists and allied health professionals. Each issue provides updates on clinical advances in malignant and benign urologic disease, health policy, legislation, malpractice, coding, and more.
Plasma ctDNA clearance may be associated with improved …
网页1 天前 · According to the authors, these findings suggest that ctDNA may be a potential biomarker to predict therapeutic benefit in these patients. The VOLGA trial is an ongoing open-label, global study assessing the combination of durvalumab plus tremelimumab plus enfortumab vedotin or durvalumab plus enfortumab vedotin vs standard of care (SOC) in patients with MIBC.
All News - Urology Times
网页Hannah Clarke. September 12th 2024. “As health care professionals, we should take a multidisciplinary approach to addressing the stress of a cancer diagnosis by helping mitigate financial toxicity, treatment burden, and emotional impact on both the patient and their family," says Mouneeb M. Choudry, MD.
Prostate Cancer | Urology News & Expert Insights | Urology Times
网页4 天之前 · August 23rd 2024. The key opinion leaders explore risk factors for prostate cancer, detailing both general risk groups and high-risk populations more susceptible to developing the disease. Ash K. Tewari, MD, on a nerve-sparing technique for robotic radical prostatectomy. Urology Times staff. August 22nd 2024.
Future directions and research on the CVAC System for kidney …
网页1 天前 · In this video, Thomas Chi, MD, MBA, discusses future directions for research and development of the CVAC System. Chi is a professor of urology, associate chair for Clinical Affairs, and the Kutzmann Endowed Professor in Clinical Urology at the University of California, San Francisco.
Bladder Cancer | Urology News & Expert Insights | Urology Times
网页2024年9月9日 · Urology Times staff. July 25th 2024. "There are many opportunities to support our patients with bladder cancer who smoke from their clinic appointments from their intravesical therapy visits to their surveillance cystoscopies," says Marc Bjurlin, DO, MSc, FACOS. Dr. Guerrero-Ramos on the evolving treatment landscape in NMIBC.
Long-term results of Rezum therapy for patients with large prostates
网页2021年12月23日 · So, the retreatment rate for our small prostate cohort was 4.4%, which is in line with the results demonstrated from the original WATER clinical trial, 3 which also had a retreatment rate of 4.4%. For our large prostate cohort, this subset of patients had a retreatment rate of 18.4%, so a little less than one in five patients required ...
New recurrent UTI guideline: What urologists need to know
网页2019年10月7日 · The index patient is an otherwise healthy adult female with an uncomplicated, culture-proven recurrent UTI associated with acute-onset symptoms. Central to a diagnosis of UTI is the symptom of dysuria. Dysuria is a highly specific symptom, with more than 90% accuracy for UTI in young women …
Novel vaccine MV140 effective at treating recurrent UTIs
网页2021年9月16日 · In a recent study, “A novel sublingual vaccine will dramatically alter the clinical management of recurrent urinary tract infections in women,” presented at the 2021 AUA annual meeting, J. Curtis Nickel, MD, and a team of investigators found that the novel MV140 vaccine is a safe and effective strategy for treating rUTI in women. 1 Nickel is a professor in the department of urology at ...